Lineage Cell Therapeutics Inc. [AMEX: LCTX] jumped around 0.18 points on Tuesday, while shares priced at $1.18 at the close of the session, up 18.00%. Lineage Cell Therapeutics Inc. stock is now 32.58% up from its year-to-date (YTD) trading value. LCTX Stock saw the intraday high of $1.20 and lowest of $0.95 per share. The company’s 52-week high price is 1.67, which means current price is +103.41% above from all time high which was touched on 02/12/20.
Compared to the average trading volume of 868.28K shares, LCTX reached a trading volume of 3536167 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
What do top market gurus say about Lineage Cell Therapeutics Inc. [LCTX]?
The Average True Range (ATR) for Lineage Cell Therapeutics Inc. is set at 0.10, with the Price to Sales ratio for LCTX stock in the period of the last 12 months amounting to 58.30. The Price to Book ratio for the last quarter was 1.66, with the Price to Cash per share for the same quarter was set at 0.17.
How has LCTX stock performed recently?
Lineage Cell Therapeutics Inc. [LCTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 29.67. With this latest performance, LCTX shares gained by 28.26% in over the last four-week period, additionally plugging by 51.09% over the last 6 months – not to mention a rise of 16.83% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LCTX stock in for the last two-week period is set at 70.34, with the RSI for the last a single of trading hit 76.01, and the three-weeks RSI is set at 64.70 for Lineage Cell Therapeutics Inc. [LCTX]. The present Moving Average for the last 50 days of trading for this stock 0.8484, while it was recorded at 0.9780 for the last single week of trading, and 0.9059 for the last 200 days.
Lineage Cell Therapeutics Inc. [LCTX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Lineage Cell Therapeutics Inc. [LCTX] shares currently have an operating margin of -2423.07 and a Gross Margin at -130.85. Lineage Cell Therapeutics Inc.’s Net Margin is presently recorded at -792.22.
Return on Total Capital for LCTX is now -33.96, given the latest momentum, and Return on Invested Capital for the company is -11.01. Return on Equity for this stock declined to -11.32, with Return on Assets sitting at -10.31. When it comes to the capital structure of this company, Lineage Cell Therapeutics Inc. [LCTX] has a Total Debt to Total Equity ratio set at 4.58. Additionally, LCTX Total Debt to Total Capital is recorded at 4.37, with Total Debt to Total Assets ending up at 4.12. Long-Term Debt to Equity for the company is recorded at 3.49, with the Long-Term Debt to Total Capital now at 3.34.
Reflecting on the efficiency of the workforce at the company, Lineage Cell Therapeutics Inc. [LCTX] managed to generate an average of -$212,891 per employee. Receivables Turnover for the company is 0.10 with a Total Asset Turnover recorded at a value of 0.01.Lineage Cell Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.50 and a Current Ratio set at 7.50.
Earnings analysis for Lineage Cell Therapeutics Inc. [LCTX]
With the latest financial reports released by the company, Lineage Cell Therapeutics Inc. posted -0.2/share EPS, while the average EPS was predicted by analysts to be reported at -0.05/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -300.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LCTX.
Insider trade positions for Lineage Cell Therapeutics Inc. [LCTX]
There are presently around $64 million, or 42.80% of LCTX stock, in the hands of institutional investors. The top three institutional holders of LCTX stocks are: BROADWOOD CAPITAL INC with ownership of 34,005,379, which is approximately 0% of the company’s market cap and around 3.70% of the total institutional ownership; BLACKROCK INC., holding 7,327,331 shares of the stock with an approximate value of $7.33 million in LCTX stocks shares; and VANGUARD GROUP INC, currently with $5.48 million in LCTX stock with ownership of nearly 0.216% of the company’s market capitalization.
Positions in Lineage Cell Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 24 institutional holders increased their position in Lineage Cell Therapeutics Inc. [AMEX:LCTX] by around 1,573,785 shares. Additionally, 43 investors decreased positions by around 1,085,664 shares, while 45 investors held positions by with 61,193,690 shares. The mentioned changes placed institutional holdings at 63,853,139 shares, according to the latest SEC report filing. LCTX stock had 6 new institutional investments in for a total of 310,339 shares, while 15 institutional investors sold positions of 138,967 shares during the same period.